Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

References

• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs18(2), 79–93 (2004).
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol.5(7), 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev. Vaccines9(2), 157–173 (2010).
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis.171(6), 1576–1585 (1995).
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Edelman R, Bryan JP et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg.51(5), 603–612 (1994).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine12(14), 1275–1280 (1994).
   PubMed Web of Science ®Google Scholar
• Rickman LS, Wistar R, Hoffman SL et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet337(8748), 998–1001 (1991).
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Arend SM, Prins C et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine28(20), 3571–3581 (2010).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med.336(2), 86–91 (1997).
   PubMed Web of Science ®Google Scholar
• André FE. Clinical experience with a recombinant DNA hepatitis B vaccine. Southeast Asian J. Trop. Med. Public Health19(3), 501–510 (1988).
   PubMedGoogle Scholar
• Vogel FR. Adjuvants in perspective. Dev. Biol. Stand.92, 241–248 (1998).
   PubMedGoogle Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci.65(20), 3231–3240 (2008).
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity33(4), 492–503 (2010).
   PubMed Web of Science ®Google Scholar
• Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol. Lett.128(1), 29–35 (2010).
   PubMed Web of Science ®Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science272(5258), 50–53 (1996).
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in tlr4 gene. Science282(5396), 2085–2088 (1998).
   PubMed Web of Science ®Google Scholar
• Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol.3(2), 169–176 (2003).
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell97(7), 889–901 (1999).
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature425(6957), 516–521 (2003).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell91(3), 295–298 (1997).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature388(6640), 394–397 (1997).
   PubMed Web of Science ®Google Scholar
• Qureshi N, Mascagni P, Ribi E, Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem.260(9), 5271–5278 (1985).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Myers K, Johnson D, Persing D, Cluff C, Hershberg R. Monophosphoryl lipid A and synthetic lipid A mimetics as TLR4-based adjuvants and immunomodulators. In: Vaccine Adjuvants: Immunological and Clinical Principles. Hackett CJ, Harn DA Jr (Eds). Humana Press Inc., Totowa, NJ, USA, 235–255 (2008).
   Google Scholar
• Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs.7(9), 1475–1482 (1998).
   PubMedGoogle Scholar
• Newman MJ, Wu JY, Gardner BH et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol.148(8), 2357–2362 (1992).
   PubMed Web of Science ®Google Scholar
• Garçon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines2(2), 231–238 (2003).
   PubMedGoogle Scholar
• Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol.183(10), 6186–6197 (2009).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Boring L, Gosling J, Chensue SW et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest.100(10), 2552–2561 (1997).
   PubMed Web of Science ®Google Scholar
• Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol.26, 421–452 (2008).
   PubMed Web of Science ®Google Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett.102(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Eddahri F, Denanglaire S, Bureau F et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood113(11), 2426–2433 (2009).
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today8(20), 934–943 (2003).
   PubMed Web of Science ®Google Scholar
• Soltysik S, Wu JY, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine13(15), 1403–1410 (1995).
   PubMed Web of Science ®Google Scholar
• Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol.1(4), 813–818 (2001).
   PubMed Web of Science ®Google Scholar
• Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine20(21–22), 2808–2815 (2002).
   PubMed Web of Science ®Google Scholar
• Rhodes J, Chen H, Hall SR et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature377(6544), 71–75 (1995).
   PubMed Web of Science ®Google Scholar
• Mettens P, Dubois PM, Demoitié MA et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine26(8), 1072–1082 (2008).
   PubMed Web of Science ®Google Scholar
• Pichyangkul S, Kum-Arb U, Yongvanitchit K et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun.76(1), 229–238 (2008).
   PubMed Web of Science ®Google Scholar
• Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol.171(12), 6961–6967 (2003).
   PubMed Web of Science ®Google Scholar
• Pichyangkul S, Tongtawe P, Kum-Arb U et al. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine28(2), 452–462 (2009).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity33(4), 451–463 (2010).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis.47(3), 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature453(7195), 667–671 (2008).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Human B cell memory. Curr. Opin. Immunol.21(3), 298–304 (2009).
   PubMed Web of Science ®Google Scholar
• Hofer T, Muehlinghaus G, Moser K et al. Adaptation of humoral memory. Immunol. Rev.211, 295–302 (2006).
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol.10(3), 193–200 (2010).
   PubMed Web of Science ®Google Scholar
• Radbruch A, Muehlinghaus G, Luger EO et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol.6(10), 741–750 (2006).
   PubMed Web of Science ®Google Scholar
• Kalia V, Sarkar S, Gourley TS, Rouse BT, Ahmed R. Differentiation of memory B and T cells. Curr. Opin. Immunol.18(3), 255–264 (2006).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol.22, 745–763 (2004).
   PubMed Web of Science ®Google Scholar
• Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science291(5512), 2413–2417 (2001).
   PubMed Web of Science ®Google Scholar
• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods65(1–2), 109–121 (1983).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55(4), 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst.92(9), 690–698 (2000).
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology384(2), 260–265 (2009).
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer89(1), 101–105 (2003).
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar
• Bosch FX, de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J. Natl Cancer Inst. Monogr. (31), 3–13 (2003).
   PubMedGoogle Scholar
• Brown DR, Shew ML, Qadadri B et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis.191(2), 182–192 (2005).
   PubMed Web of Science ®Google Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med.102(5A), 3–8 (1997).
   PubMedGoogle Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol.32(Suppl. 1), S16–S24 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol. Oncol.110(3 Suppl. 1), S1–S10 (2008).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet370(9590), 890–907 (2007).
   PubMed Web of Science ®Google Scholar
• Deschuyteneer M, Elouahabi A, Plainchamp D et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccin.6(5), 407–419 (2010).
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Immunopotentiators in Modern Vaccines. Elsevier Academic Press, London, UK, 161–178 (2006).
   Google Scholar
• Kemp TJ, García-Piñeres A, Falk RT et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine26(29–30), 3608–3616 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Kocken M, Petäjä T et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum. Vaccin.6(12), 1054–1061 (2010).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine27(4), 581–587 (2009).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccin.5(10), 705–719 (2009).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev. Vaccines7(10), 1465–1473 (2008).
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba PC, Naud PS et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet374(9706), 1975–1985 (2009).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• de Carvalho N, Teixeira J, Roteli-Martins CM et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine28(38), 6247–6255 (2010).
   PubMed Web of Science ®Google Scholar
• Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a Phase 2 double-blind, randomized controlled trial. Int. J. Gynecol. Cancer20(5), 847–855 (2010).
   PubMed Web of Science ®Google Scholar
• Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a Phase 2 double-blind, randomized, controlled trial. Int. J. Gynecol. Cancer20(3), 404–410 (2010).
   PubMed Web of Science ®Google Scholar
• Bhatla N, Suri V, Basu P et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res.36(1), 123–132 (2010).
   PubMed Web of Science ®Google Scholar
• Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a Phase II, double-blind, randomized controlled trial at month 7. Int. J. Gynecol. Cancer19(5), 905–911 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim KT, Kim JH et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10–14 years. J. Korean Med. Sci.25(8), 1197–1204 (2010).
   PubMed Web of Science ®Google Scholar
• Ngan HY, Cheung AN, Tam KF et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med. J.16(3), 171–179 (2010).
   PubMedGoogle Scholar
• David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol.115(Suppl. 3), S1–S6 (2009).
   PubMed Web of Science ®Google Scholar
• Petäjä T, Keränen H, Karppa T et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J. Adolesc. Health44(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Rivera Medina DM, Valencia A, de Velasquez A et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J. Adolesc. Health46(5), 414–421 (2010).
   PubMed Web of Science ®Google Scholar
• Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv. Ther.26(11), 983–998 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Schwarz TF, Carmona A et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria–tetanus–acellular pertussis-inactivated poliovirus vaccine to girls and young women. J. Adolesc. Health46(2), 142–151 (2010).
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther.8(2), 235–247 (2008).
   PubMed Web of Science ®Google Scholar
• Kong NC, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68(5), 2298–2303 (2005).
   PubMed Web of Science ®Google Scholar
• Kong NC, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int.73(7), 856–862 (2008).
   PubMed Web of Science ®Google Scholar
• Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines8(8), 1023–1035 (2009).
   PubMed Web of Science ®Google Scholar
• Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis.186(Suppl. 1), S3–S28 (2002).
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Diefenbach RJ, Miranda-Saksena M et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis.194(Suppl. 1), S11–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med.361(14), 1376–1385 (2009).
   PubMed Web of Science ®Google Scholar
• Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ.86(10), 805–812 (2008).
   PubMed Web of Science ®Google Scholar
• Bourne N, Bravo FJ, Francotte M et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis.187(4), 542–549 (2003).
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347(21), 1652–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin.5(5), 1–9 (2009).
   Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David MP et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine26(51), 6630–6638 (2008).
   PubMed Web of Science ®Google Scholar
• Greenwood BM, Fidock DA, Kyle DE et al. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest.118(4), 1266–1276 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccin.6(1), 90–96 (2010).
   PubMed Web of Science ®Google Scholar
• Singh AP, Buscaglia CA, Wang Q et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell131(3), 492–504 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clin. Microbiol. Rev.19(4), 686–707 (2006).
   PubMed Web of Science ®Google Scholar
• Egan JE, Weber JL, Ballou WR et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science236(4800), 453–456 (1987).
   PubMed Web of Science ®Google Scholar
• Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med.151(6), 1504–1513 (1980).
   PubMed Web of Science ®Google Scholar
• Frevert U, Nardin E. Cellular effector mechanisms against Plasmodium liver stages. Cell. Microbiol.10(10), 1956–1967 (2008).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358(9297), 1927–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364(9443), 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366(9502), 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Vekemans J, Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines7(2), 223–240 (2008).
   PubMed Web of Science ®Google Scholar
• Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine27(Suppl. 6), G67–G71 (2009).
   PubMed Web of Science ®Google Scholar
• Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis.200(3), 329–336 (2009).
   PubMed Web of Science ®Google Scholar
• Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet370(9598), 1543–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Barbosa A, Naniche D, Aponte JJ et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect. Immun.77(10), 4502–4509 (2009).
   PubMed Web of Science ®Google Scholar
• Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med.359(24), 2533–2544 (2008).
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med.359(24), 2521–2532 (2008).
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O et al. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis.200(3), 337–346 (2009).
   PubMed Web of Science ®Google Scholar
• Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE4(7), e6465 (2009).
   PubMed Web of Science ®Google Scholar
• Waitumbi JN, Anyona SB, Hunja CW et al. Impact of RTS,S/AS02A and RTS,S/AS01B on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS ONE4(11), e7849 (2009).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine24(42–43), 6483–6492 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun.75(5), 2283–2290 (2007).
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE4(10), e7302 (2009).
   PubMed Web of Science ®Google Scholar
• Lell B, Agnandji S, von Glasenapp I et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE4(10), e7611 (2009).
   PubMed Web of Science ®Google Scholar
• Guinovart C, Aponte JJ, Sacarlal J et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLoS ONE4(4), e5165 (2009).
   PubMed Web of Science ®Google Scholar
• Audran R, Lurati-Ruiz F, Genton B et al. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled Phase I trial. PLoS ONE4(10), e7304 (2009).
   PubMed Web of Science ®Google Scholar
• Polhemus ME, Magill AJ, Cummings JF et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine25(21), 4203–4212 (2007).
   PubMed Web of Science ®Google Scholar
• Spring MD, Cummings JF, Ockenhouse CF et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE4(4), e5254 (2009).
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a Phase 1 randomized controlled trial. PLoS ONE3(1), e1465 (2008).
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a Phase 1 randomized controlled trial. PLoS ONE5(2), e9041 (2010).
   PubMed Web of Science ®Google Scholar
• Roestenberg M, Remarque E, de Jonge E et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02. PLoS ONE3(12), e3960 (2008).
   PubMed Web of Science ®Google Scholar
• Ogutu BR, Apollo OJ, McKinney D et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE4(3), e4708 (2009).
   PubMed Web of Science ®Google Scholar
• Cummings JF, Spring MD, Schwenk RJ et al. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine28(31), 5135–5144 (2010).
   PubMed Web of Science ®Google Scholar
• Hollingdale MR, Aikawa M, Atkinson CT et al. Non-CS pre-erythrocytic protective antigens. Immunol. Lett.25(1–3), 71–76 (1990).
   PubMed Web of Science ®Google Scholar
• Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol.67(1), 59–68 (1994).
   PubMed Web of Science ®Google Scholar
• Diggs CL, Ballou WR, Miller LH. The major merozoite surface protein as a malaria vaccine target. Parasitol. Today9(8), 300–302 (1993).
   PubMedGoogle Scholar
• Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol.17(5), 219–223 (2001).
   PubMed Web of Science ®Google Scholar
• Silvie O, Franetich JF, Charrin S et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem.279(10), 9490–9496 (2004).
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Mapping the future of HIV vaccines. Nat. Rev. Microbiol.5(7), 482–484 (2007).
   PubMed Web of Science ®Google Scholar
• McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity33(4), 542–554 (2010).
   PubMed Web of Science ®Google Scholar
• Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature464(7286), 224–231 (2010).
   PubMed Web of Science ®Google Scholar
• Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol. Cell. Biol.1–8 (2010).
   Web of Science ®Google Scholar
• Montefiori DC, Mascola JR. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr. Opin. HIV AIDS4(5), 347–351 (2009).
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Tomaras GD, Horton H et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine25(3), 510–518 (2007).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Koutsoukos M, Clementa F et al. Strong and persistent CD4+ T cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine28(43), 7016–7024 (2010).
   PubMed Web of Science ®Google Scholar
• Van Braeckel E, Bourguignon P, Koutsoukos M et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin. Infect. Dis.52(4), 522–531 (2011).
   PubMed Web of Science ®Google Scholar
• Coplan PM, Gupta SB, Dubey SA et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J. Infect. Dis.191(9), 1427–1434 (2005).
   PubMed Web of Science ®Google Scholar
• Potter SJ, Lacabaratz C, Lambotte O et al. Preserved central memory and activated effector memory CD4+ T cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol.81(24), 13904–13915 (2007).
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Kapogiannis BG, Ibegbu C et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol.81(21), 12071–12076 (2007).
   PubMed Web of Science ®Google Scholar
• Lichterfeld M, Kaufmann DE, Yu XG et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med.200(6), 701–712 (2004).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Letvin NL. CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr. Opin. Immunol.13(4), 479–482 (2001).
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood107(12), 4781–4789 (2006).
   PubMed Web of Science ®Google Scholar
• Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med.189(6), 991–998 (1999).
   PubMed Web of Science ®Google Scholar
• Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS23(8), 897–906 (2009).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature449(7158), 101–104 (2007).
   PubMed Web of Science ®Google Scholar
• Andersen P. Tuberculosis vaccines – an update. Nat. Rev. Microbiol.5(7), 484–487 (2007).
   PubMed Web of Science ®Google Scholar
• Dye C, Williams BG. The population dynamics and control of tuberculosis. Science328(5980), 856–861 (2010).
   PubMed Web of Science ®Google Scholar
• Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don’t know can, and does, hurt us. Science328(5980), 852–856 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet375(9731), 2110–2119 (2010).
   PubMed Web of Science ®Google Scholar
• Reed SG, Coler RN, Dalemans W et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl Acad. Sci. USA106(7), 2301–2306 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol.26(12), 660–667 (2005).
   PubMed Web of Science ®Google Scholar
• Von Eschen K, Morrison R, Braun M et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vaccin.5(7), 475–482 (2009).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Lodes MJ, Guderian JA et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. Immun.67(8), 3998–4007 (1999).
   PubMed Web of Science ®Google Scholar
• Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AS, Dalemans W, Skeiky YA. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin. Exp. Immunol.138(1), 139–144 (2004).
   PubMed Web of Science ®Google Scholar
• Montoya J, Solon JA, Acosta L et al. An antigen and adjuvant system dose ranging safety and immunogenicity study of the M72 candidate tuberculosis vaccines in healthy Filipino adults. Trop. Med. Int. Health14(Suppl. 2), 42 (2009) (Abstract).
   Google Scholar
• Surquin M, Tielemans CL, Kulcsar I et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine. Kidney Int77(3), 247–255 (2010).
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Lau GK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine25(51), 8585–8597 (2007).
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine26(10), 1375–1386 (2008).
   PubMed Web of Science ®Google Scholar
• Beran J, Hobzova L, Wertzova V et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum. Vaccin.6(7), 578–584 (2010).
   PubMed Web of Science ®Google Scholar
• Gérard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol. Oncol.3(5–6), 409–424 (2009).
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther.8(7), 951–968 (2008).
   PubMed Web of Science ®Google Scholar
• Vantomme V, Dantinne C, Amrani N et al. Immunologic analysis of a Phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother.27(2), 124–135 (2004).
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol.12, 337–365 (1994).
   PubMed Web of Science ®Google Scholar
• Szmania S, Gnjatic S, Tricot G et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J. Immunother.30(8), 847–854 (2007).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol.172(5), 3289–3296 (2004).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Cao Y et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl Acad. Sci. USA105(5), 1650–1655 (2008).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol.25, 7554 (2007) (Abstract).
   Web of Science ®Google Scholar
• Kruit WH, Suciu S, Dreno B et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group. J. Clin. Oncol.26(15 Suppl.), 9065 (2008).
   Google Scholar
• Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat. Immunol.6(9), 873–879 (2005).
   PubMed Web of Science ®Google Scholar
• Koopman G, Mortier D, Hofman S et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol.89(Pt 2), 540–553 (2008).
   PubMed Web of Science ®Google Scholar
• Sacarlal J, Aponte JJ, Aide P et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine26(2), 174–184 (2008).
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine26(18), 2191–2202 (2008).
   PubMed Web of Science ®Google Scholar